Lactosylated Glycogen Nanoparticles for Targeting Prostate Cancer Cells.
Quinn A BesfordMarcin WojnilowiczTomoya SumaNadja Bertleff-ZieschangFrank CarusoFrancesca CavalieriPublished in: ACS applied materials & interfaces (2017)
Glyconanoparticles that exhibit multivalent binding to lectins are desirable for molecular recognition and therapeutic applications. Herein we explore the use of glycogen nanoparticles as a biosourced glycoscaffold for engineering multivalent glyconanoparticles. Glycogen nanoparticles, a naturally occurring highly branched polymer of glucose, was functionalized with lactose, achieved through copper(I)-catalyzed alkyne-azide cycloaddition chemistry, for targeted interaction with lectins ex situ and on prostate cancer cells. The lactosylated glycogen, which contains terminal β-galactoside moieties, is termed galacto-glycogen (GG), and is found to interact strongly with peanut agglutinin (PNA), a β-galactoside-specific lectin, as observed by optical waveguide lightmode spectroscopy, dynamic light scattering, and quartz crystal microbalance measurements. The GG nanoparticles exhibit multivalent binding to PNA with an affinity constant of 3.4 × 105 M-1, and the GG-PNA complex cannot be displaced by lactose, demonstrating the competitive binding of GG to the lectin. These GG nanoparticles were tested for association with prostate cancer cell membranes in vitro, where the particles exhibited a high affinity for the membrane, as observed from flow cytometry and confocal microscopy. This is inferred to result from specific extracellular galectin-1 targeting. Furthermore, the GG nanoparticles induce aggregation between prostate cancer cells. Our results highlight a strategy for engineering a biosourced polysaccharide with surface moieties that exhibit strong multivalent interactions with lectins, and targeted interaction with prostate cancer cells.